Inclusion and Exclusion Criteria
We included only peer reviewed articles published in English in the medical literature that were clinical trials, epidemiological studies, observational studies, cohort studies, review articles or case-control studies exploring a direct link between COPD and CI. Book chapters, grey-literature, animal studies, qualitative research papers and studies where full-text was not available were excluded. Studies which based on the title or abstract were clearly irrelevant (e.g investigating lung transplantation in COPD, investigating inhaler use in CI), did not measure CI as a specific outcome or did not specifically investigate a link between COPD and CI were excluded. Protein and interleukin-6 (1,2). These may contribute to cognitive dysfunction via a direct neurotoxic effect or by contributing to cerebral atherosclerosis (3) with studies suggesting a dose-response relationship (1) .
Clusterin is a glycoprotein expressed in the majority of human tissues(4) Previous studies state peripheral levels of clusterin are raised in CI and neuronal inflammation (5) . The concentrations increased in the mild-moderate and severe COPD groups compared with controls (both p<0.01), being significantly higher in the severe COPD group compared to the mild-moderate group (p<0.01) as well. Level of cognitive dyfunction, reflected by the MMSE score, was correlated with clusterin levels in COPD (r=0.33, p<0.01). While this study showed an association between COPD severity, levels of peripheral clusterin and cognitive dysfunction a direct link has not yet been proven. Although age, BMI, sex and education levels were matched, other factors such as co-morbidity could have confounded. S100B is a calcium-binding protein expressed mainly by astrocytes. Chronic neurodegenerative conditions such as Alzheimer's disease have been shown to lead to peripherally increased levels of this protein. It is also used as a marker for CI; levels negatively correlated with MMSE scores (6)(7) measured the serum S100B levels across three groups. Serum S100B levels increased significantly in the mild-to-moderate (p<0.01) and severe COPD (P<0.01) groups compared with the control group. In addition, the serum S100B concentration was significantly higher in the severe COPD group than that in the mild-to-moderate COPD group (P<0.01). The study concluded that further investigation is needed to address the underlying mechanisms. This is in keeping with increased systemic markers, such as S100B in Alzheimer's, being related to the level of cognitive dysfunction. Further investigation of this is required to establish if there are specific inflammatory markers mediating CI unique to COPD.
Differences in brain structure in COPD
The hippocampus forms part of the limbic system in the medial temporal lobe. It plays a role in memory, spatial awareness and is particularly vulnerable to hypoxemia (7) . Magnetic Resonance Imaging (MRI) studies have found that atrophy of the hippocampal region is consistent with mild CI and Alzheimer's disease (8).
Li et al. (2013)(7) investigated effects of hypoxaemia on hippocampal volume. Findings showed chronic hypoxaemia correlated with decreased hippocampal volume in COPD patients, leading to hippocampal atrophy resulting in CI. Of note, there were no significant differences of hippocampal volumes between mild-moderate and severe COPD groups. The study hypothesized that the cumulative loss of neurons and their connections results in hippocampal atrophy in the early stage of the disease, while the structural change converts to the functional deterioration in later stages. The mechanisms of these structural changes are poorly understood, however a possible explanation is that hypoxaemia has particularly adverse effects on the hippocampus, and possibly the wider limbic system. Further research specifically comparing hippocampal volume in COPD and non-COPD patients would be of value.
Antonelli-Incalzi et al (2003)(9) investigated cerebral perfusion using Single Photon Emission Computed Tomography (SPECT) and compared to neuropsychological assessment scores in normal, hypoxaemic COPD, non-hypoxaemic COPD and known Alzheimer's Disease (AD) patients. COPD groups scored less than controls in the domains of verbal attainment, attention and deductive thinking. SPECT scanning identified anterior cerebral hypoperfusion; the authors suggested this could precede frontal-type cognitive decline in hypoxaemic patients. (11) found that only 78% of their cohort and 47% of those with CI could adequately complete lung function testing. Therefore, it is difficult to accurately assess any association of CI and FEV 1 if CI patients cannot perform spirometry.
Limitations of this review
A limitation of the SR is that only two databases were searched, and expert authors in the field were not contacted to identify relevant papers or identify the grey literature. As such the review may have been subject to selection bias and publication bias. The review was limited to 2010-2015 as a high quality systematic review of the subject was published in 2012 (5)and a large scale review was published by Dodd in 2010(12); we intended to build on and add to the literature regarding this subject to contextualise the background for the cross-sectional study. 
